Adverse Events Associated With Antibody-Drug Conjugates Across Cancer Types
Researchers say they have identified adverse events that are more likely to occur in cancer patients receiving antibody-drug conjugates.
Diagnosis & Disease Information
Diabetes Increases Risk of Upstaging in RCC
Diabetes increases the likelihood of upstaging in patients with clinical T1 RCC undergoing partial or radical nephrectomy, a study suggests.
Belzutifan Gets Priority Review for Advanced Renal Cell Carcinoma
The FDA has accepted for priority review the supplemental new drug application for belzutifan to treat adults with advanced renal cell carcinoma who previously received immune checkpoint and anti-angiogenic therapies.
Cancer Patients With ICI-Induced Acute Pancreatitis May Require Imaging, Monitoring
Cancer patients with ICI-induced acute pancreatitis may require abdominal imaging for diagnosis and monitoring for exocrine pancreatic insufficiency.
Lymphovascular Invasion Ups Mortality Risk in Kidney Cancer Surgery
Investigators believe their study is the first to demonstrate the adverse impact of LVI on overall survival in patients with surgically treated renal cell carcinoma.
Managing Ocular Side Effects of Immune Checkpoint Inhibitors
Ocular side effects of immune checkpoint inhibitors are considered rare but may be underreported.
US Cancer Death Rates on the Decline, but Urban/Rural Divide Persists
Cancer death rates have declined in the United States in recent years, but the declines are greater in urban than in rural areas, data suggest.
Researchers Quantify Risk of Hypertension, LVSD in AYAs With Kidney Cancer
Adolescents and young adults (AYAs) with kidney cancer have a similar risk of left ventricular systolic dysfunction and a lower risk of hypertension than non-AYAs, research suggests.
Wastage of Oral Cancer Drugs Costs More Than $4000 per Patient, Study Suggests
Researchers studied 22 oral cancer drugs and found that wastage due to dose modifications or discontinuations resulted in a mean cost of $4290 per patient.
Lung Cancer Patients Hospitalized With irAEs Due to ICIs Have Shorter Survival
Lung cancer patients treated with immune checkpoint inhibitors experience worse immune-related adverse event survival than other cancer patients.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...